Drug intelligence / Profile preview

ABO-103

Development stage: Preclinical
Lead developer: Arbor Biotechnologies
Modality: Gene Therapies, Nanoparticles → Drug Delivery Systems

Overview

ABO-103 is an investigational gene editing program developed by Arbor Biotechnologies. It utilizes RT Editing technology, delivered via Lipid Nanoparticles (LNP). While the specific target and indication remain undisclosed, the program is currently in various stages of development, including discovery, lead optimization, IND-enabling studies, and has reached Phase 1/2.

Targets

HAO1 (Glycolate Oxidase)

Beyond the preview

Go deeper on ABO-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABO-103.

Explore the full profile